Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1994 2
1995 3
1996 2
1997 6
1998 6
1999 6
2000 7
2001 5
2002 8
2003 6
2004 15
2005 13
2006 14
2007 12
2008 17
2009 31
2010 39
2011 41
2012 39
2013 49
2014 45
2015 44
2016 55
2017 43
2018 39
2019 45
2020 50
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

562 results
Results by year
Filters applied: . Clear all
Page 1
Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H, Tanimoto K, Terakura S, Murata M, Inaguma Y, Masuya M, Inoue N, Kidokoro T, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Naoe T, Emi N, Yasukawa M, Katayama N, Shiku H. Tawara I, et al. Blood. 2017 Nov 2;130(18):1985-1994. doi: 10.1182/blood-2017-06-791202. Epub 2017 Aug 31. Blood. 2017. PMID: 28860210 Clinical Trial.
Wilms' tumor 1 (WT1) is constantly expressed in leukemic cells of acute leukemia and myelodysplastic syndrome (MDS). A T-cell receptor (TCR) that specifically reacts with WT1 peptide in the context of HLA-A*24:02 has been identified. We conducted a first-in-human tr …
Wilms' tumor 1 (WT1) is constantly expressed in leukemic cells of acute leukemia and myelodysplastic syndrome (MDS). A T-cell recepto …
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG, Voillet V, Gottardo R, Ragnarsson GB, Bleakley M, Yeung CC, Muhlhauser P, Nguyen HN, Kropp LA, Castelli L, Wagener F, Hunter D, Lindberg M, Cohen K, Seese A, McElrath MJ, Duerkopp N, Gooley TA, Greenberg PD. Chapuis AG, et al. Nat Med. 2019 Jul;25(7):1064-1072. doi: 10.1038/s41591-019-0472-9. Epub 2019 Jun 24. Nat Med. 2019. PMID: 31235963 Free PMC article.
As graft T cells have not been selected for leukemia specificity and frequently recognize proteins expressed by many normal host tissues, graft-versus-leukemia effects are often accompanied by morbidity and mortality from graft-versus-host disease(5). Thus, AML relapse ris …
As graft T cells have not been selected for leukemia specificity and frequently recognize proteins expressed by many normal host tissues, gr …
WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, Wang P, Yang H, Ma S, Lin H, Jiao B, Ren R, Ye D, Guan KL, Xiong Y. Wang Y, et al. Mol Cell. 2015 Feb 19;57(4):662-673. doi: 10.1016/j.molcel.2014.12.023. Epub 2015 Jan 15. Mol Cell. 2015. PMID: 25601757 Free PMC article.
The interaction between WT1 and TET2 is disrupted by multiple AML-derived TET2 mutations. ...Our results also provide an explanation for the mutual exclusivity of WT1 and TET2 mutations in AML, and suggest an IDH1/2-TET2-WT1 pathway in suppressi …
The interaction between WT1 and TET2 is disrupted by multiple AML-derived TET2 mutations. ...Our results also provide an expla …
Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
Handschuh L, Kaźmierczak M, Milewski MC, Góralski M, Łuczak M, Wojtaszewska M, Uszczyńska-Ratajczak B, Lewandowski K, Komarnicki M, Figlerowicz M. Handschuh L, et al. Int J Oncol. 2018 Mar;52(3):656-678. doi: 10.3892/ijo.2017.4233. Epub 2017 Dec 28. Int J Oncol. 2018. PMID: 29286103 Free PMC article. Clinical Trial.
The overexpression of the CPA3 gene was specific for AML with mutated NPM1 and FLT3. Although the microarray-based method was insufficient to differentiate between any other AML subgroups, quantitative PCR approaches enabled us to identify 3 genes (ANXA3, S100A9 and …
The overexpression of the CPA3 gene was specific for AML with mutated NPM1 and FLT3. Although the microarray-based method was insuffi …
WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).
Steger B, Floro L, Amberger DC, Kroell T, Tischer J, Kolb HJ, Schmetzer HM. Steger B, et al. J Immunother. 2020 Jul/Aug;43(6):204-215. doi: 10.1097/CJI.0000000000000322. J Immunother. 2020. PMID: 32502139
Here, we studied the expression levels of the immunogenic antigens PRAME (preferentially expressed antigen of melanoma), WT1 (Wilms' tumor gene), and PR3 (proteinase 3) on myeloid blasts by real-time quantitative polymerase chain reaction and correlated these data to the s …
Here, we studied the expression levels of the immunogenic antigens PRAME (preferentially expressed antigen of melanoma), WT1 (Wilms' …
Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation.
Liu H, Wang X, Zhang H, Wang J, Chen Y, Ma T, Shi J, Kang Y, Xi J, Wang M, Zhang M. Liu H, et al. Mol Med Rep. 2019 Sep;20(3):2426-2432. doi: 10.3892/mmr.2019.10440. Epub 2019 Jun 28. Mol Med Rep. 2019. PMID: 31257540
The expression level of WT1 was significantly lower in patients with remission compared with patients with early-stage and recurrent AML. ...WT1 expression was significantly reduced during remission. In patients with AML who underwent allogeneic hemato …
The expression level of WT1 was significantly lower in patients with remission compared with patients with early-stage and recurrent …
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, Tallman MS, Scheinberg DA. Maslak PG, et al. Blood Adv. 2018 Feb 13;2(3):224-234. doi: 10.1182/bloodadvances.2017014175. Blood Adv. 2018. PMID: 29386195 Free PMC article. Clinical Trial.
A National Cancer Institute consensus study on prioritization of cancer antigens ranked the Wilms tumor 1 (WT1) protein as the top immunotherapy target in cancer. We previously reported a pilot study of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute mye …
A National Cancer Institute consensus study on prioritization of cancer antigens ranked the Wilms tumor 1 (WT1) protein as the top im …
Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia.
Niktoreh N, Walter C, Zimmermann M, von Neuhoff C, von Neuhoff N, Rasche M, Waack K, Creutzig U, Hanenberg H, Reinhardt D. Niktoreh N, et al. J Oncol. 2019 Jul 30;2019:1609128. doi: 10.1155/2019/1609128. eCollection 2019. J Oncol. 2019. PMID: 31467532 Free PMC article.
To re-evaluate the effect of these factors in contemporary protocols, 353 patients (<18 years) treated in Germany with AML-BFM treatment protocols between 2004 and 2017 were included. Presence of mutated WT1 and FLT3-ITD in blasts (n=19) resulted in low 3-year ev …
To re-evaluate the effect of these factors in contemporary protocols, 353 patients (<18 years) treated in Germany with AML-BFM tre …
The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis.
Long J, Fang S, Dai Q, Liu X, Zhu W, Wang S. Long J, et al. Oncotarget. 2016 May 31;7(22):32079-87. doi: 10.18632/oncotarget.8117. Oncotarget. 2016. PMID: 26992216 Free PMC article. Review.
In the subgroup analyses of age, race, and subtype of AML, WT1 rs16754 polymorphism was a independent favorable-risk marker. In conclusion, WT1 rs16754 polymorphism is associated with better survival of AML. ...
In the subgroup analyses of age, race, and subtype of AML, WT1 rs16754 polymorphism was a independent favorable-risk marker. I …
Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones.
de Boer B, Prick J, Pruis MG, Keane P, Imperato MR, Jaques J, Brouwers-Vos AZ, Hogeling SM, Woolthuis CM, Nijk MT, Diepstra A, Wandinger S, Versele M, Attar RM, Cockerill PN, Huls G, Vellenga E, Mulder AB, Bonifer C, Schuringa JJ. de Boer B, et al. Cancer Cell. 2018 Oct 8;34(4):674-689.e8. doi: 10.1016/j.ccell.2018.08.014. Epub 2018 Sep 20. Cancer Cell. 2018. PMID: 30245083 Free article.
To address this problem, we performed label-free quantitative proteomics on primary acute myeloid leukemia (AML) samples. We identified 50 leukemia-enriched plasma membrane proteins enabling the prospective isolation of genetically distinct subclones from individual AML
To address this problem, we performed label-free quantitative proteomics on primary acute myeloid leukemia (AML) samples. We identifi …
562 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page